logo
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate

USA Today15 hours ago
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that it is forging ahead with advancing its lead candidate NV-387 into Phase II clinical drug development.
NanoViricides has chosen MPox as the first indication to advance NV-387 into Phase II clinical trials out of the four indications for which the Company has substantial efficacy data in animal studies, namely RSV, Influenza, COVID, and Orthopoxviruses (MPox/Smallpox).
The MPox program enables advancing its pipeline towards revenue in the fastest possible manner, the Company believes. The Company intends to advance NV-387 against respiratory infections soon after the Phase II clinical trial of NV-387 for the treatment of MPox infection gets under way.
NanoViricides has already added one Clinical trial Site to the MPox Phase II Program.
A Phase II Clinical Trial Protocol has been developed with the Principal Investigator at this site in the Democratic Republic of Congo (DRC), and this Protocol is undergoing final refinements.
A Clinical Trial Application is in development with many parts having been substantially completed.
NanoViricides has engaged a Clinical Research Organization (CRO) to organize and conduct this Phase II clinical trial for the treatment of MPox with NV-387, as previously stated, and this CRO has organized the Clinical Trial Site and is preparing the CTA with the Company's inputs.
The manufacture of the drug substance NV-387 is substantially completed at the Company's own facility. The manufacture of the drug product 'NV-387 Oral Gummies' is in progress.
MPox as the first indication has several strategic benefits for the Company.
Firstly, because of the continuing epidemic in the African Region there is a strong need for the drug and also there is the ability to recruit patients and complete the clinical trial in a timely manner. Additionally, running clinical trials in the African Region is substantially less expensive than clinical trials in USA or Europe that the Company has planned for RSV, a commercially important indication with multi-billion dollar potential market.
Secondly, a proof of efficacy in humans of NV-387 against MPox would validate our use of lethal challenge animal models and would establish that our animal model data are predictive of human outcomes. This would have huge implications since our animal model data against every infection we have tested to date has demonstrated NV-387 to be substantially superior to existing drugs, viz. RSV, Influenza, COVID, and of course, MPox/Smallpox.
Thirdly, there is a strong financial case for choosing MPox as the indication. This business case has become even stronger with the failure of tecovirimat (Tpoxx) in clinical trial against MPox. Tecovirimat and brincidofovir (Tembexa) are the only two drugs approved by the US FDA for the treatment of Smallpox, a virus of bioterrorism concern. Both of these drugs were approved under the 'FDA Animal Rule', which eliminates the need for demonstration of efficacy in humans. The 'FDA Animal Rule' is applicable for diseases such as Smallpox and others where clinical trials in human patients are not feasible or would be unethical.
These FDA approvals have led to the acquisition of these two drugs into the US Strategic National Stockpile (SNS) to the tune of billions of dollars. And now, there is a clear need for replacing these non-performing drugs with a drug that actually works against MPox and Smallpox (see further down below).
We believe NV-387 would become the choice for addition to the SNS if our proposed Phase II clinical trial against MPox demonstrates benefits of the NV-387 treatment.
The most recent acquisition contracts with BARDA for tecovirimat, which were for drug replenishments, have been valued at over $150million.
An initial stocking contract for NV-387 is likely to be substantially larger, as was the case with the initial acquisition of several drugs into the SNS.
Brincidofovir failed an early clinical trial against MPox due to liver toxicity. Tecovirimat failed a recent clinical trial against MPox since it demonstrated no superiority in efficacy over the standard of care.
Importantly, both of these drug candidates are small chemicals that the viruses can readily escape by mutations. Smallpox, if it ever becomes fielded as a bio-terrorism agent, is unlikely to be in the 'original' form of the virus, and could be explicitly manipulated to breed resistance to such small chemical drugs by onerous entities.
Of note, MPox is in the same family as the Smallpox virus; MPox causes a much weaker form of disease than the Smallpox virus.
Thus there is a strong case for HHS to support NV-387 drug development for Bioterrorism Readiness.
The 'NV-387 Oral Gummies' drug product is a soft solid formulation that is designed to stick in the oral cavity and dissolve naturally over time, with no solid object (pill or capsule) swallowing necessary. This is important for MPox because MPox causes lesions on mucosal surfaces that make swallowing painful and difficult. MPox is primarily known for the explicit characteristic painful rash on the external skin, but it is a significantly more severe disease than just a skin rash.
The MPox virus circulating in DRC and neighboring regions is of Clade 1a and Clade 1b subtypes, with the latter predominant. Clade 1b is more transmissible of the two, which is why it has resulted in a sustained epidemic. The MPox Clade 1a case fatality rate (CFR) is about 3%-11% whereas the CFR for Clade 1b is about 1%. The MPox Clade 2b is the virus causing continuing cases in the Western world, which causes a much less severe disease than Clade 1a/1b and has a very low CFR, according to CDC. Sporadic cases of Clade 1 in the Western world continue to occur. Four separate travel-related MPox Clade 1 cases reported in the USA that did not result in any further spread, since November 2024, according to the CDC ( https://www.cdc.gov/mpox/situation-summary/index.html ). Clearly, the threat of MPox Clade 1 causing a potential epidemic in the USA cannot be ignored, and readiness with a drug that works against the same is important to achieve.
ABOUT NANOVIRICIDES
NanoViricides, Inc. (the 'Company') ( www.nanoviricides.com ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development.
Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
SOURCE: NanoViricides, Inc.
View the original press release on ACCESS Newswire
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tutor Perini Building Corp. Awarded $220 Million Eagle Mountain Casino Phase 2 Expansion
Tutor Perini Building Corp. Awarded $220 Million Eagle Mountain Casino Phase 2 Expansion

Business Wire

time26 minutes ago

  • Business Wire

Tutor Perini Building Corp. Awarded $220 Million Eagle Mountain Casino Phase 2 Expansion

LOS ANGELES--(BUSINESS WIRE)--Tutor Perini Corporation (NYSE: TPC) (the 'Company'), a leading civil, building and specialty construction company, announced today that its subsidiary, Tutor Perini Building Corp., has been awarded a contract by the Tule River Gaming Authority valued at approximately $220 million for the Eagle Mountain Casino Phase 2 Expansion. The project is located in Porterville, California. The scope of work includes construction of a new 193-room tower with a rooftop restaurant, a central warehouse and offices, expansion of an existing restaurant, a new 2,000-seat events center with convention space, breakout meeting rooms, pre-function space, and new hotel amenities, including a new spa, arcade and resort pool. Work is expected to commence in the summer of 2025 with substantial completion anticipated in 2027. The contract value is being incrementally added to the Company's backlog, beginning with the preconstruction phase award that was booked in the second quarter of 2025 and later this year as subsequent construction phases are anticipated to be awarded by the customer. About Tutor Perini Corporation Tutor Perini Corporation is a leading civil, building and specialty construction company offering diversified general contracting and design-build services to private customers and public agencies throughout the world. We have provided construction services since 1894 and have established a strong reputation within our markets by executing large, complex projects on time and within budget while adhering to strict safety and quality control measures. We offer general contracting, pre-construction planning and comprehensive project management services, and have strong expertise in delivering design-bid-build, design-build, construction management, and public-private partnership (P3) projects. We often self-perform multiple project components, including earthwork, excavation, concrete forming and placement, steel erection, electrical, mechanical, plumbing, heating, ventilation and air conditioning (HVAC), and fire protection.

Why Mamdani's rent freeze means disaster for NYC tenants
Why Mamdani's rent freeze means disaster for NYC tenants

New York Post

time3 hours ago

  • New York Post

Why Mamdani's rent freeze means disaster for NYC tenants

New York City's rental housing market is teetering on the edge of disaster — with a Mamdani mayoralty poised to push it off the cliff. His success running as a 'freeze the rent' candidate has already moved the Rent Guidelines Board to OK dangerously low hikes for rent-stabilized units: 3% for one-year lease renewals, 4.5% for two-year ones — far less than what RGB staff report those landlords' costs are rising at. Zero and near-zero rent hikes in the de Blasio years — RGB rents are up just 20% these last 12 years, vs. overall inflation of 36% — followed by widespread rent nonpayment during COVID (plus state 'reforms' that make it unaffordable to renovate units vacated by longtime tenants), already has many rent-stabilized landlords, especially smaller ones, on the brink of having to abandon their buildings altogether. Others have no choice but to stint on maintenance, letting buildings and units deteriorate; everyone loses as these apartments grow shabbier and more scarce. If Mamdani wins and sticks to his vow to appoint RGB members who'll freeze rents, the bottom is all too likely to fall out. And the new mayor's fans will have a far tougher time finding a decent apartment in New York. By the way, how many Zohran supporters realize that he can't freeze most rents? The rent-stabilized units that the RGB governs are less than half the city's formal rental market, and at most a third of the full city housing supply, once you count coops and condos (even if sublet) and actual houses. And a shrinking of the rent-controlled market is sure to push up prices of market-rate units, big time, because even more people will be chasing a smaller total supply. Incidentally, this effect explains the 'record landlord profits' that Mamdani ally Brad Lander has been thundering about: It's landlord income from rents the city doesn't control. Small, mom-and-pop landlords, who own about two-thirds of city's rent-stabilized units, are the ones who'll get reamed by the freeze (even though they're the little people that lefties claim to care about). Tens of thousands of units are in dire shape in The Bronx alone. Economists almost universally acknowledge that rent control is ruinous to housing markets; ones on the left mostly just don't talk about it, lest it make it harder for 'their side' to win elections. The rent-freeze advocates have no idea how they're destroying New York's housing market — for the very people most desperate for apartments. They're also likely ignorant about who benefits from below-market rents — i.e., folks who, like Mamdani, scored a rent-stabilized apartment, which is actually easier if you're wealthy (as he is). One more irony here: The Supreme Court last year nixed New York landlords' claim that the rent laws violate the Constitution's 'takings' clause. Thing is, that ruling relied on the assumption that the RGB has real independence — a fiction that will collapse if Mamdani wins on promises platform of 0% hikes and then delivers.

EACO Corporation Reports Record Quarter Net Sales and Record Quarter Net Income
EACO Corporation Reports Record Quarter Net Sales and Record Quarter Net Income

Business Wire

time3 hours ago

  • Business Wire

EACO Corporation Reports Record Quarter Net Sales and Record Quarter Net Income

ANAHEIM, Calif.--(BUSINESS WIRE)--EACO Corporation (OTCMKTS:EACO) today reported the results for its quarter ended May 31, 2025. EACO Corporation reports Record Quarter net sales and Record Quarter income. Share Net sales, net income and earnings per share were as follows for the three months ended May 31, 2025 and 2024 (dollars in thousands, except per share information): The Company had 435 sales employees at May 31, 2025, an increase of 36 employees or 9%, from the prior year quarter. The Company's sales force is divided into sales focus teams (SFT's). The Company had 114 SFT's as of May 31, 2025, four more than the prior year quarter. Management anticipates continued growth in both our headcount and SFT's in fiscal year 2025. The Company believes it continues to gain market share through its local presence business model. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains certain forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1955, as amended. These forward-looking statements include, without limitation, statements related to our headcount expansion, growth in market share, and other statement that is not historical information. These forward-looking statements are based on our current expectations and are inherently subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. The potential risks and uncertainties include, but are not limited to, our ability to hire and retain additional qualified employees, our ability to open additional sales offices, and to gain market acceptance for our products, the pricing and availability of our products, the success of our sales and marketing programs, the impact of products offered by our competitors from time to time, and as well as increases to international tariffs. In addition to these factors and any other factors mentioned elsewhere in this news release, the reader should refer as well to the factors, uncertainties or risks identified in EACO's most recent Form 10-K and all subsequent Form 10-Q reports filed by us with the SEC. The forward-looking statements included in this release speak only as of the date hereof, and EACO does not undertake any obligation to update these forward-looking statements to reflect subsequent events or circumstances. EACO Corporation and Subsidiaries Condensed Consolidated Balance Sheets (unaudited) May 31, 2025 2024* ASSETS Current Assets: Cash and cash equivalents $ 3,613 $ 843 Restricted cash 10 10 Trade accounts receivable, net 59,875 53,272 Inventory, net 82,780 69,602 Marketable securities, trading 22,063 14,748 Prepaid expenses and other current assets 3,491 3,526 Total current assets 171,832 142,001 Non-current Assets: Property, equipment and leasehold improvements, net 34,368 35,061 Operating lease right-of-use assets 6,739 7,513 Other assets, net 3,989 3,963 Total assets $ 216,928 $ 188,538 LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Trade accounts payable $ 37,067 $ 28,054 Accrued expenses and other current liabilities 21,494 24,910 Current portion of long-term debt 131 129 Current portion of operating lease liabilities 2,674 2,708 Total current liabilities 61,366 55,801 Non-current Liabilities: Line of Credit 491 – Long-term debt 4,116 4,214 Operating lease liabilities 4,222 4,892 Total liabilities 70,195 64,907 Commitments and Contingencies Note 9 Shareholders' Equity: Convertible preferred stock, $0.01 par value per share; 10,000,000 shares authorized; 36,000 shares outstanding (liquidation value $900) 1 1 Common stock, $0.01 par value per share; 8,000,000 shares authorized; 4,861,590 shares outstanding 49 49 Additional paid-in capital 12,378 12,378 Accumulated other comprehensive income 66 73 Retained earnings 134,239 111,130 Total shareholders' equity 146,733 123,631 Total liabilities and shareholders' equity $ 216,928 $ 188,538 * Derived from the Company's audited financial statements included in its Form 10-K for the year ended August 31, 2024 filed with the U.S. Securities and Exchange Commission on November 29, 2024. Expand EACO Corporation and Subsidiaries Condensed Consolidated Statements of Income (in thousands, except for share and per share information) (unaudited) Three Months Ended May 31, Nine Months Ended May 31, 2025 2024 2025 2024 Net sales $ 111,410 $ 96,121 $ 305,462 $ 259,711 Cost of sales 77,337 68,193 214,100 183,184 Gross margin 34,073 27,928 91,362 76,527 Operating expenses: Selling, general and administrative expenses 21,627 26,314 60,979 61,129 Impairment on termination of lease - – - 3,906 Income from operations 12,446 1,614 30,383 11,492 Other income (expense): Net gain (loss) on trading securities 277 (24) 761 (45) Interest and other (expense) (46) (44) (143) (128) Other income (expense), net 231 (68) 618 (173) Income before income taxes 12,677 1,546 31,001 11,319 Provision for income taxes 3,162 362 7,835 2,858 Net income 9,515 1,184 23,166 8,461 Cumulative preferred stock dividend (19) (19) (57) (57) Net income attributable to common shareholders $ 9,496 $ 1,165 $ 23,109 $ 8,404 Basic earnings per share: $ 1.95 $ 0.24 $ 4.75 $ 1.73 Diluted earnings per share: $ 1.94 $ 0.24 $ 4.73 $ 1.73 Basic weighted average common shares outstanding 4,861,590 4,861,590 4,861,590 4,861,590 Expand EACO Corporation and Subsidiaries Condensed Consolidated Statements of Cash Flows (in thousands) (unaudited) Nine Months Ended May 31, 2025 2024 Operating activities: Net income $ 23,166 $ 8,461 Adjustments to reconcile net income to net cash (used in) provided by operating activities: Depreciation and amortization 1,268 1,247 Bad debt expense 203 359 Deferred tax provision (18) 51 Net unrealized (gain) loss on trading securities (205) 357 Impairment on termination of lease – 3,906 Increase (decrease) in cash flow from change in: Trade accounts receivable (6,806) (7,764) Inventory (13,178) (11,139) Prepaid expenses and other assets 27 98 Operating lease right-of-use assets 774 5,490 Trade accounts payable 6,268 8,043 Accrued expenses and other current liabilities (3,416) 785 Operating lease liabilities (704) (5,501) Net cash provided by operating activities 7,379 4,393 Investing activities: Purchase of property, equipment, and leasehold improvements (575) (32,527) Net (purchases) sales of marketable securities, trading (7,110) 17,466 Net cash used in investing activities (7,685) (15,061) Financing activities: Borrowings on revolving credit facility 491 – Repayments on long-term debt (96) (94) Preferred stock dividend (57) (57) Bank overdraft 2,745 3,066 Net cash provided by financing activities 3,083 2,915 Effect of foreign currency exchange rate changes on cash and cash equivalents (7) (68) Net increase (decrease) in cash, cash equivalents, and restricted cash 2,770 (7,821) Cash, cash equivalents, and restricted cash - beginning of period 853 8,568 Cash, cash equivalents, and restricted cash - end of period $ 3,623 $ 747 Supplemental disclosures of cash flow information: Cash paid for interest $ 143 $ 145 Cash paid for income taxes $ 9,213 $ 8,276 Expand

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store